BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.50 +1.07%
Revenue Growth %: +13.2%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
